Otsuka America Pharmaceutical, Inc. And Lundbeck Inc. To Present Data On Investigational Compound Brexpiprazole In Schizophrenia And Major Depressive Disorder At American Psychiatric Association Annual Meeting

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck today announced the presentation of several posters highlighting pre-clinical and clinical trial data for brexpiprazole, a novel investigational compound currently under review by the FDA as a potential monotherapy in adults with schizophrenia and as an adjunctive therapy in adults with major depressive disorder. The eight posters will be presented during the upcoming American Psychiatric Association (APA) annual meeting in Toronto, Canada, May 16-20.

Help employers find you! Check out all the jobs and post your resume.

Back to news